by Eric Christianson | Feb 4, 2026 | Cardiovascular Medication and Disease State Clinical Pearls
Rhabdomyolysis happens when muscle cells break down and release their contents into the blood. These substances can damage the kidneys and cause serious problems like kidney failure. It is often triggered by medications, injuries, extreme exercise, or drug...
by Eric Christianson | Jan 14, 2024 | Cardiovascular Medication and Disease State Clinical Pearls
Fenofibrate is a lipid-lowering medication indicated as monotherapy to treat primary hyperlipidemia, mixed dyslipidemia, and hypertriglyceridemia. While this medication has been around for many years, its formulation has continued to evolve. The different fenofibrate...
by Eric Christianson | Jan 22, 2023 | Cardiovascular Medication and Disease State Clinical Pearls
It is always controversial to come up with a top 5 list but we went for it. Below we have put together a list of the top 5 landmark trials in hyperlipidemia management. (NOTE: This is part of a bigger project that I am working on with Sarah Zahirudin, PharmD,...
by Eric Christianson | Jan 23, 2019 | Clinical Guideline Updates For Pharmacists
In late 2018, ACC and AHA came out with an update to their cholesterol guidelines. The last update was from 2013 so PCSK-9 inhibitors hadn’t even been approved at that time. Very High Risk Patients – My Biggest Takeaway I always had a hard time knowing...
